{"id":"NCT01939158","sponsor":"Pfizer","briefTitle":"Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine","officialTitle":"A PHASE III, RANDOMISED, OPEN, CONTROLLED, MULTICENTRE, PRIMARY VACCINATION STUDY TO EVALUATE THE IMMUNOGENICITY AND PERSISTENCE OF 1 AND 2 DOSES OF MENINGOCOCCAL CONJUGATE VACCINE MENACWY-TT IN TODDLERS (AFTER 1 MONTH AND UP TO 5 YEARS) AND TO DEMONSTRATE NON-INFERIORITY OF CO-ADMINISTRATION OF MENACWY-TT AND 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE PREVENAR 13(REGISTERED) VERSUS SEPARATE ADMINISTRATION OF THE 2 VACCINES","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10-02","primaryCompletion":"2019-12-05","completion":"2019-12-05","firstPosted":"2013-09-11","resultsPosted":"2021-10-05","lastUpdate":"2021-10-05"},"enrollment":803,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal vaccine GSK134612","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevenar 13™","otherNames":[]}],"arms":[{"label":"ACWY1d group","type":"EXPERIMENTAL"},{"label":"ACWY2d group","type":"EXPERIMENTAL"},{"label":"Co-ad group","type":"EXPERIMENTAL"},{"label":"PCV-13 group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the immediate and long term (up to 5 years) immunogenicity and safety of GSK Biologicals' MenACWY-TT vaccine when given as a single dose or as 2 doses to toddlers aged 12 to 14 months. Also, this study will also assess if co-administration of GSK Biologicals' MenACWY-TT with the booster dose of Pfizer's Prevenar 13 adversely impacts the immunogenicity of either of the vaccines.","primaryOutcome":{"measure":"Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement Antibody (rSBA) Titers >=1:8 at 1 Month After Administration of 1 Dose of MenACWY-TT in the ACWY1d, ACWY2d and Co-ad Groups","timeFrame":"1 month after administration of 1st dose of MenACWY-TT (i.e. at Month 1)","effectByArm":[{"arm":"ACWY1d Group","deltaMin":97.8,"sd":null},{"arm":"ACWY2d Group","deltaMin":96.8,"sd":null},{"arm":"Co-ad Group","deltaMin":94.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":16},"locations":{"siteCount":51,"countries":["Australia","Canada","Czechia","Panama","South Africa","Turkey (Türkiye)"]},"refs":{"pmids":["36621408"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=MENACWY-TT-104&StudyName=A+Phase+Iii%2C+Randomised%2C+Open%2C+Controlled%2C+Multicentre%2C+Primary+Vaccination+Study+To+Evaluate+The+Immunogenicity+And+Persistence+Of+1+And+2+Doses+Of+Meningococcal+Conjugate+Vaccine+Menacwy-tt+In+Toddlers+%28after+1+Month+And+Up+To+5+Years%29+And+To+Demonstrate+Non-inferiority+Of+Co-administration+Of+Menacwy-tt+And+13-valent+Pneumococcal+Conjugate+Vaccine+Prevenar+13%28registered%29+Versus+Separate+Administration+Of+The+2+Vaccines"]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":203},"commonTop":["Irritability/Fussiness","Redness","Drowsiness","Pain","Loss Of Appetite"]}}